KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biocryst Pharmaceuticals (BCRX) EBIAT (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed EBIAT for 9 consecutive years, with $245.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIAT rose 1017.5% year-over-year to $245.8 million, compared with a TTM value of $263.9 million through Dec 2025, up 396.87%, and an annual FY2025 reading of $263.9 million, up 396.87% over the prior year.
  • EBIAT was $245.8 million for Q4 2025 at Biocryst Pharmaceuticals, up from $12.9 million in the prior quarter.
  • Across five years, EBIAT topped out at $245.8 million in Q4 2025 and bottomed at -$201.7 million in Q4 2023.
  • Average EBIAT over 3 years is -$3.0 million, with a median of -$12.7 million recorded in 2024.
  • The sharpest move saw EBIAT surged 86.71% in 2024, then soared 1017.5% in 2025.
  • Year by year, EBIAT stood at -$201.7 million in 2023, then soared by 86.71% to -$26.8 million in 2024, then skyrocketed by 1017.5% to $245.8 million in 2025.
  • Business Quant data shows EBIAT for BCRX at $245.8 million in Q4 2025, $12.9 million in Q3 2025, and $5.1 million in Q2 2025.